Abstract
BACKGROUND: In this study, association of between drop-out and inflamation were investigated in peritoneal dialysis (PD) patients with end-stage renal failure (ESRF) .METHOD: Of the 150 ESRF patients who were started with or switched to PD, 46 drop-out patients were evaluated retrospectively. Patients demographic characteristics, drop-out and inflamation markers as albumin levels, CRP levels and fibrinogen levels were researched. The laboratory results were taken as the average of the last three months.RESULTS: In the drop-out group mean decrease in serum albumin and mean increase in C-reactive protein and fibrinogen was significantly different from the other group (p<0.001, p<0.001, p<0.05, respectively). When demographic characteristics, diabetes mellitus, and hypertension status was evaluated, the difference was not significant (p> 0.05).CONCLUSİON : Infllammation markers should be used to asses the drop-out of peritoneal dialysis patients.

Keywords
Chronic renal failure, peritoneal dialysis, C-reactive proteine, albümin, fibrinogen, drop-out

Cite this paper
Ali BORAZAN, Gulistan YOLDAS, Ayse Semra DEMİR AKCA, Association between drop-out and inflamation in peritoneal dialysis patients , SCIREA Journal of Clinical Medicine. Volume 2, Issue 1, February 2017 | PP. 1-9.

References

[ 1 ]	Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol.2012;23:533–44.
[ 2 ]	Verger C, Ryckelynck JP, Duman M, Veniez G, Lobbedaz T, Boulanger E, et al. French Peritoneal Dialysis Registry (RDPLF): Outline and main results. Kidney Int Suppl 2006; 103: 12-20.
[ 3 ]	Han SH, Lee JE, Kim DK, Moon SJ, Kim HW, Chang JH, et al. Long-term clinical outcomes of peritoneal dialysis patients: Single center experience from Korea. Perit Dial Int 2008; 28(3): S21-6.
[ 4 ]	Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894–900.
[ 5 ]	Young DO, Lund RJ, Haynatzki G, Dunlay RW. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int 2007;11:86–95.
[ 6 ]	Tsangalis G, Papaconstantinou S, Kosmadakis G, Valis D, Zerefos N. Prevalence of the metabolic syndrome in hemodialysis. Int J Artif Organs 2007; 30: 118–23.
[ 7 ]	Murphy SW, Foley RN, Parfey PJ. National Kidney Foundation Task Force on cardiovascular disease: screening and treatment for cardiovascular disease in patients with cronic renal disease. Am J Kidney Dis 1998;32(5):184-99
[ 8 ]	Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999–2002). Nephrol Dial Transplant 2004; 19: 2584–2591.
[ 9 ]	Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol 2010; 6: 451–460.
[ 10 ]	Li PK, Chow KM. The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. Perit Dial Int 2005; 25(3):80–83.
[ 11 ]	Herzig KA , Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol. 2001;12:814–821.
[ 12 ]	Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1998;18:387–394.
[ 13 ]	Carrero J, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol. 2009;4(1):49–55.
[ 14 ]	Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P. Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif. 2008;26:291–299.
[ 15 ]	Kaysen GA, Dubin JA, Müller HG, Mitch WE, Rosales L, Levin NW. Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. Kidney Int. 2003;63:315–322.
[ 16 ]	Kaysen GA, Dubin JA, Müller HG, Mitch WE, Rosales LM, Levin NW. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int.2002; 61: 2240–2249.
[ 17 ]	Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong Association between Malnutrition, Inflammation, and Atherosclerosis in Chronic Renal Failure. Kidney Int 1999;55: 1899–911.
[ 18 ]	Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29: 658–68.
[ 19 ]	Garibotto G, Sofia A, Procopio V, Villaggio B, Tarroni A, Di Martino M, et al. Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: Effects of end-stage renal disease and microinflammatory state. Kidney Int 2006; 70: 384-390.
[ 20 ]	Lacson E Jr and Levin NW: C-reactive protein and end-stage renal disease. Semin Dial 2004; 17: 438-448.
[ 21 ]	Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-45.
[ 22 ]	Kaysen GA: Inflammation: cause of vascular disease and malnutrition in dialysis patients. Semin Nephrol 2004; 24: 431-436.
[ 23 ]	Kronenberg F. Homocysteine, lipoprotein (a) and fibrinogen: Metabolic risk factors for cardiovascular complications of chronic renal disease. Curr Opin Nephrol Hypertens 1998;7:271–8.
[ 24 ]	Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis. 1998;137:133–13.